Volume 16 Number 6 (March 15th, 2008) reporting from: 4th European Congress on Hematologic Malignancies (February 22-24, 2008, Paris) American Society of Hematology Annual Meeting (December 8-11, 2007
Volume 16 Number 6 (March 15th, 2008) reporting from:
4th European Congress on Hematologic Malignancies (February 22-24, 2008, Paris)
American Society of Hematology Annual Meeting (December 8-11, 2007 Atlanta)
Chemotherapy Foundation Symposium, November 7-10, 2007, New York
David Maloney
Nonmyeloablative Alogeneic Transplants Ready for Prime-Time in Follicular Lymphoma?
David Maloney, Fred Hutchinson Cancer Research Center, Seattle
Allogeneic transplantation is now a good option for treating some patient groups with follicular lymphoma.David Maloneyexplained to Peter Goodwin in Paris how his group has harnessed graft-versus-tumor effect by using nonmyeloablative conditioning without causing unacceptable risks of graft-versus-host disease.
Carolyn Krasner
Trabectedin Activity in Platinum-Sensitive Relapsed Ovarian Cancer
Carolyn Krasner, Massachusetts General Hospital, Boston
Could trabectedin, which has a novel mechanism of action, be a useful agent for patients with relapsed ovarian cancer? Derek Thorne discussed this question in New York withCarolyn Krasner, whose data show the greatest benefit in patients who are sensitive to platinum agents.
Kirk Schultz
Armand Keating
High-Dose Chemotherapy Plus Imatinib Benefits Pediatric Acute Lymphoblastic Leukemia
Kirk Schultz, British Columbia Children’s Hospital, VancouverCOMMENT:Armand Keating, Princess Margaret Hospital, Toronto
For children with acute lymphoblastic leukemia, high-dose chemotherapy combined with imatinib appears to show a survival benefit. Sarah Maxwell spoke with study authorKirk Schultzat the ASH meeting in Atlanta, andArmand Keatingprovided comment.
John Gribben
Chronic Lymphocytic Leukemia: New Options After Fludarabine Failure
John Gribben, Bartholemews Hospital, London
New treatments for chronic lymphocytic leukemia were discussed in Paris byJohn Gribben. He gave Peter Goodwin his assessment of antibody therapies such as rituximab and alemtuzumab and new drugs such as lenalidomide, and combinations including standard fludarabine therapy.
To subscribe to the ASCO Audio Journal of Oncology podcast please go toASCO Audio Journal of Oncology in Advance Presentationsorclick here.
Related Episodes
Hassan Mohammed Abushukair MD; AACR 2026: Immune Checkpoint Inhibitor-Induced Myocarditis within One Month Predicts Lethal “Triple M Overlap Syndrome”
Immune Checkpoint Inhibitor-Induced Myocarditis within One Month Predicts Lethal “Triple M Overlap Syndrome” An interview with: Hassan Mohammed Abushukair MD, Post-Doctoral Researcher, Oklahoma Univer
Aditya Bardia MD MPH; 2025 San Antonio Breast Cancer Symposium: Selective Estrogen Degrader Giredestrant Improves on Standard Endocrine Therapy for Patients with ER-positive, HER2-negative Early Breast Cancer: Phase III lidERA Breast Cancer trial Findings
A seective estrogen degrader out-performed AI’s in ER+ HER- early breast cancer
Li Zhang MD; ESMO 2025: Patients with EGFR-mutated Lung Cancer Progressing After Tyrosine Kinase Therapy Live Longer with Sacituzumab Tirumotecan Therapy
Antibody Drug Conjugate Prolongs Life in NSCLC refractory to EGFR TKI Therapy